Figure 7.

Sorafenib inhibits the EMT phenotype and fibroblast activation in vivo. Following a single treatment with 3.5 mg/kg bleomycin (BLM) at day 0, the mice received sorafenib (5 mg/kg) or vehicle by gavage once per day for 12 days (from days 3 to 14). (a–e) The sections of pulmonary tissues were subjected to immunohistochemical analysis using antibodies as indicated in the figures. Brown coloration indicates positive staining and white arrows point to representative double-positive cells. (f) Real-time PCR was performed to detect the mRNA levels of Claudin, E-cadherin, FSP1 and α-SMA in the pulmonary tissues from each group. *P<0.05; **P<0.01, sorafenib-treated group versus BLM-treated group